UCSF

Tagged: cancer

Unmasking a cellular hallmark of cancer

Scientists identify a signature of cancers caused by mutant RAS that may lead to precise therapies.

Guo applies curiosity and collaboration to research

“There are lots of important problems. Only attack those for which you can divine simple experiments with clear answers.”
—Julius Axelrod

This quotation is a guiding principle for Su Guo, PhD, professor in the Department of Bioengineering and Therapeutic Sciences (BTS). Her research employs the unique strengths of a simple vertebrate, the zebrafish (Danio rerio), to address a wide variety of topics related to neuroscience.

Renslo Lab develops new type of targeted chemotherapy that proves effective in mice

Research in the lab of UCSF School of Pharmacy faculty member Adam Renslo, PhD, has developed a new way of selectively targeting cancer cells with drugs. In experiments with mice, the new approach allowed for the delivery of fifty times higher doses of chemotherapy to tumors while avoiding toxic effects on healthy cells.

Research: Elusive drug targets; cell demolition enzymes; useful pharmacogenomics info

Predicting difficult-to-detect drug binding sites

UCSF School of Pharmacy leads in NIH funding for 36th year in a row

For the 36th consecutive year, the UCSF School of Pharmacy has received more funding from the National Institutes of Health (NIH) than any other pharmacy school in the United States.

Fragment-based discovery: using smaller molecules to solve larger challenges

To discover new drugs and chemical probes, researchers have traditionally screened small molecules—small enough by weight to pass through cell membranes. Their goal is typically to find compounds that selectively bind to a much larger protein molecule (often an enzyme) at a chemically reactive pocket known as the active site, inhibiting its activity to treat a disease or to better understand a biological process.

Abate honored by White House with Presidential Early Career Award

UCSF School of Pharmacy faculty member Adam Abate, PhD, has been named a recipient of the Presidential Early Career Award for Scientists and Engineers, the highest honor bestowed by the U.S. government on science and engineering professionals in the early stages of their independent research careers.

Abate and 104 fellow recipients of the White House honor will formally receive their awards at a Washington, DC, ceremony this spring.

Altschuler and Wu develop new cell-screening approach to speed drug discovery

How do you discover new drugs against diseases such as cancer?

Kroetz leads new study of genetics of cancer drugs’ dose-limiting side effects

Taxanes are a class of drugs widely used to treat a variety of cancers, including breast, ovarian, lung, gastric, and head and neck. But dosages are often limited by toxic side effects—most commonly damage to the body’s peripheral nerves, causing numbness, pain, and/or hyper-sensitivity—that can require reduced or suspended treatment and which can linger for years in disease survivors.

Danica Galonic Fujimori, PhD

Associate Professor

I am interested in the development of novel chemical tools that allow us to interrogate biological processes on a molecular level with the ultimate goal of developing novel therapeutic strategies for the treatment of cancer and infectious diseases.

Pages